Key Findings:
In a phase 2 trial presented at the European Alliance of Associations for Rheumatology (EULAR) 2024 Annual Meeting, sonelokimab demonstrated significant efficacy in treating patients with active psoriatic arthritis (PsA). Sonelokimab, a nanobody targeting interleukin (IL)-17A and IL-17F, led to a notable increase in the percentage of patients achieving a 50% or greater improvement in American College of Rheumatology response criteria (ACR50) compared to placebo.
Methodology:
Sonelokimab, a 40-kDa nanobody, binds to IL-17A, IL-17F, and albumin. The trial included 207 eligible patients aged 18 and older with active PsA and a history of psoriasis. Patients were randomized into four groups receiving placebo, sonelokimab 60 mg without induction, sonelokimab 60 mg with induction, and sonelokimab 120 mg with induction. The induction regimen involved doses every 2 weeks up to week 8.
Key Results:
- Approximately 46% of patients receiving sonelokimab 120 mg and 60 mg achieved ACR50, compared to 36.6% in the non-induction sonelokimab 60 mg group and 20% in the placebo group.
- All sonelokimab groups showed higher response rates for ACR20 and a 90% or greater reduction in Psoriasis Area and Severity Index (PASI) scores compared to placebo.
- Safety findings were favorable, with no unexpected issues reported. Two cases of oral candidiasis were noted, neither resulting in study discontinuation.
Clinical Implications:
The promising phase 2 results support further investigation of sonelokimab in phase 3 trials for its potential as a PsA treatment option. According to the authors, these findings warrant continued exploration into the therapeutic benefits of sonelokimab.
Source and Disclosures:
Presented by Iain B. McInnes, MD, PhD, of the University of Glasgow, Scotland, the trial was funded by MoonLake Immunotherapeutics. Dr. McInnes disclosed multiple relationships with pharmaceutical companies, including MoonLake Immunotherapeutics, AbbVie, Amgen, and others.
Limitations:
As a phase 2 trial, further research is necessary to fully establish the efficacy and safety profile of sonelokimab in treating PsA.
This article summarizes the significant strides made by sonelokimab in improving outcomes for patients with active psoriatic arthritis, marking a potential advancement in rheumatologic care.
Related Topics:
